Literature DB >> 16483643

Electrothermal bipolar coagulation for pelvic exenterations.

Brian M Slomovitz1, Pedro T Ramirez, Michael Frumovitz, Pamela T Soliman, Michael Bevers, Robert L Coleman, Charles Levenback.   

Abstract

OBJECTIVES: The morbidity associated with pelvic exenteration is high; however, patients undergoing this procedure have no other curative treatment options. Excessive blood loss is a common complication of this procedure. We evaluated whether use of an electrothermal bipolar coagulator (LigaSure Atlas, ValleyLab, Boulder, Colorado, USA) during pelvic exenteration is safe and whether it reduces intraoperative blood loss, intraoperative blood transfusion requirements, and length of hospital stay.
METHODS: Between September 2003 and January 2005, 12 patients underwent pelvic exenteration (total, anterior, or posterior) performed using the electrothermal bipolar coagulator. Estimated blood loss, transfusion requirements, length of hospital stay, and complications necessitating reoperation were evaluated.
RESULTS: The mean age was 55 years (range, 30-77), the mean estimated blood loss was 1931 ml (range, 1300-1500 ml), the mean number of units of packed red blood cells transfused intraoperatively was 3.4 U (range, 2-12 U), the mean operative time was 609 min (range, 400-940 min), and the mean length of hospital stay was 19.9 days (range, 7-27). There were no intraoperative complications related to the electrothermal bipolar coagulator use. None of the patients had any complications necessitating reoperation.
CONCLUSIONS: Use of the electrothermal bipolar coagulator device during pelvic exenteration is safe and may decrease blood loss and the number of units of blood that must be transfused intraoperatively.

Entities:  

Mesh:

Year:  2006        PMID: 16483643     DOI: 10.1016/j.ygyno.2006.01.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

2.  Overall survival after pelvic exenteration for gynecologic malignancy.

Authors:  Shannon N Westin; Vijayashri Rallapalli; Bryan Fellman; Diana L Urbauer; Navdeep Pal; Michael M Frumovitz; Lois M Ramondetta; Diane C Bodurka; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2014-07-09       Impact factor: 5.482

3.  LigaSure Impact™ versus conventional dissection technique in pylorus-preserving pancreatoduodenectomy in clinical suspicion of cancerous tumours on the head of the pancreas: study protocol for a randomised controlled trial.

Authors:  Tobias Gehrig; Phillip Knebel; Verena Scheel; Ulf Hinz; Christoph M Seiler; Beat P Müller-Stich; Markus W Büchler; Carsten N Gutt
Journal:  Trials       Date:  2011-06-29       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.